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Background: Smoking status has been linked to several chronic inflammatory conditions but earlier research on
smoking and celiac disease (CD) is contradictive. There are little data on moist snuff use and CD. The purpose of
this study was to investigate the association between smoking, moist snuff use and later CD.
Methods: We identified individuals with biopsy-verified CD (villous atrophy, histopathology stage Marsh III) through
biopsy-reports from Sweden’s 28 pathology departments. Data on smoking and moist snuff were collected from
the Swedish construction worker database “Bygghälsan” that includes preventive health care check-up data.
Through poisson regression we calculated relative risks (RRs) for later CD according to smoking status (n = 305,722),
and moist snuff status (n = 199,200) adjusting for age, sex and decade.
Results: During follow-up 488 individuals with smoking data, and 310 with moist snuff data had a diagnosis of CD.
The risk of CD was independent of smoking status with all RRs being statistically insignificant and ranging between
0.9 and 1.0. Compared to non-smokers, neither current smokers (RR = 0.93; 95% CI = 0.76-1.14) nor ex-smokers
(RR = 0.98; 95% CI = 0.75-1.28) were at increased or decreased risk of CD. Risk estimates were similar in moderate
smokers (RR = 0.92; 0.72-1.16) and heavy smokers (RR = 0.95; 0.74-1.24), and did not change when we examined
the risk more than ten years after health examination (RR-moderate: 0.90; and RR-heavy: 0.95; both p > 0.05).
Moist snuff use was not associated with later CD (RR = 1.00; 0.78-1.28), or with CD after more than ten years of
follow-up (RR = 1.05; 0.80-1.38).
Conclusions: We found no association between smoking, moist snuff use and future CD.
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Celiac disease (CD) is characterized by small intestinal in-
flammation and is triggered by gluten exposure in genetic-
ally sensitive individuals [1]. CD occurs in 1-2% of the
Western population [2,3], and has been linked to a number
of disorders including type 1 diabetes [4], sepsis [5], lym-
phoproliferative malignancy [6], and excess mortality [7].
Although almost all individuals with CD are DQ2+ or
DQ8+, genetic factors alone cannot explain the risk of CD
[8]. Several environmental factors have therefore been put
forward as explanations for CD (short breastfeeding [9],
and to a lesser extent early infections [10,11] and elective* Correspondence: jonasludvigsson@yahoo.com
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article, unless otherwise stated.caesarean section [12]), and stressful life events (such as
pregnancy, death of relatives or surgery etc [13,14].
Most environmental risk factors have however only
been studied in patients with childhood CD, and there is
a lack of knowledge about CD risk factors in adults.
Smoking has been linked to a number of inflammatory
disorders [15] including Crohn’s disease [16], and for a
number of gastrointestinal disorders the association seems
to be protective (e.g. ulcerative colitis [17] and sclerosing
cholangitis [18]). Most earlier studies have shown an in-
verse relationship also between CD and smoking [19-24],
but there are exceptions [25,26]. The largest study to date
reported a positive association between smoking and CD
[26] (Figure 1).
Smokeless tobacco (moist snuff ) contains nicotine,
which may influence the degree of intestinal inflamma-
tion. Moist snuff use in pregnant women has recentlytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Relationship between smoking and celiac disease (CD). Relationship between smoking and celiac disease (CD). CD, celiac disease.
Y-axis shows adjusted odds ratio/relative risk and 95% confidence intervals for CD in current smokers. Number of included patients with CD:
Snook (n = 86) [22], Todi (n = 330) [21], Vazquez (n = 87) [19]; Patel (n = 82) [25], Austin (n = 430) [20], West (n = 87) [24], Suman (n = 138) [23],
Ludvigsson (undiagnosed (a): n = 237; and diagnosed (b): n = 636) [26], and current study (n = 488). # The studies by Austin et al [20] and Thomasson
et al [27] (not included in Figure 1) seem to be based on the same datasets. Thomasson et al do not present any odds ratio for CD among
smokers but re-calculating their data we found a crude OR of 0.51, which is almost identical to that of Austin et al (crude OR = 0.52). For this
reason the Thomasson et al study has not been included in Figure 1. § (a) association between smoking and undiagnosed CD; (b) association
between smoking and diagnosed CD.
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a positive association with inflammatory bowel disease
[29]. We are unaware of any studies examining its asso-
ciation with CD.
In the current prospective study, we investigated the
risk of CD among smokers and moist snuff users. Smok-
ing and moist snuff are also contrasted as a means to
disentangle the potential effect of nicotine exposure (oc-
curs in both) on CD as opposed to effects of substances
that only occur in tobacco smoke.
Methods
Through the personal identity number [30] we linked
data on smoking and moist snuff use obtained from
some Swedish construction workers [31,32], with data
on CD from Sweden’s 28 pathology departments [33].
Smoking and moist snuff use
Between 1971 and 1993, results from health examina-
tions of white- and blue-collar workers in the Swedish
construction industry were computerized. The workers
were offered preventive health check-ups by a national
occupational health service, “Bygghälsan”. Data on health
and exposures were collected through questionnaire, and
a face-to-face interview by dedicated nurses. During 1975-
77 no tobacco data were collected.
We categorized smoking into three groups (never,
former, or current), and then subdivided current into
moderate (≤14 cigarettes per day or equivalent), and
heavy smokers (≥15 cigarettes per day). Moist snuff was
divided into “ever” and “never users” for those with in-
formation after 1978. For the period 1971-74 onlycurrent snuff users were included as the variable for
non-current users also included those who had not an-
swered. Therefore, the analysis of moist snuff users was
based on 199,185 persons (82,572 ever and 116,613
never users). Less than 10% of the ever-users reported
that they had stopped using moist snuff. The quality of
smoking data has been reviewed by Engholm et al and is
high [34]. A previous review of smoking data at the first
and second health examination (2–3 years apart) among
18,593 subjects in the “Bygghälsan” cohort found a 89%
perfect match with data [35]. Inconsistencies regarding
never-smoking status (study participants first indicated
that they were current/former smokers in one question-
naire and then reported never-smoking in the second
questionnaire) were reported for 2.7% [35].
The original cohort consisted of 389,132 individuals,
369,174 men and 19,418 women. Of those, 15 individ-
uals were excluded because they had a diagnosis of CD
before health examination. The mean year of birth in
the remaining cohort was 1944 (range 1891-1976), mean
year of first examination 1978.8 and mean age at first
examination 34.6 years (range 14-82 years).
The number of recorded health examinations ranged
from 1 to 15, with an average of 3. In this study we con-
sistently used information on smoking and moist snuff
from the first recorded visit (also defined as start of
follow-up). There was information on tobacco smoking
for 305,722 persons (290,449 men and 15,273 women).
Information on moist snuff was available for 199,185
persons (187,338 men and 11,847 women).
Details of ethics approval: The study was approved by
the Regional ethical review board in Umeå, 2013/225-31.
Table 1 Smoking habits in the cohort (N = 305,722 and
cases with CD (N = 488)




Moderate smokers 24.2 22.5
Heavy smokers 17.1 16.7
Table 2 Relative risk of CD according to smoking status
Smoking status
RR# 95% CI§
Latency > =0 years*
Non-smokers 1.00
Ex-smokers 0.98 0.75-1.28
Moderate smokers 0.92 0.72-1.16
Heavy smokers 0.95 0.74-1.24
Latency > =10 years*
Non-smokers 1.00
Ex-smokers 0.99 0.75-1.31
Moderate smokers 0.90 0.70-1.16
Heavy smokers 0.95 0.72-1.27
RR, Relative risk adjusted for age, sex and decade.
1.00 constitutes reference.
*≥ years since health examination where the smoking habits were decided.
#Poisson regression analysis (age in 10-year-intervals).
§Wald estimates.
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Between October 2006 and February 2008, we contacted
all 28 Swedish pathology departments and obtained bi-
opsy report data on duodenal and jejunal biopsies car-
ried out in 1969-2008. IT personnel retrieved local data
on date of biopsy, topography (duodenum or jejunum),
morphology codes consistent with villous atrophy (histo-
pathology stage Marsh III; see earlier paper for details
[33]), as well as personal identity number [30]. Biopsy
reports were on average based on 3 tissue specimen
[36]. In this paper villous atrophy equals CD.
After removal of data irregularities, we had informa-
tion on 29,148 individuals with CD [33]. After excluding
two individuals with potentially incorrect date of birth,
there remained 29,146 individuals. CD was the outcome
measure of our study.
Statistics
Person-years of follow up were calculated for each person
from year of health examination within the construction
worker service through 31 December 2008, CD, death or
emigration, whichever occurred first. The person-years
were stratified for age (10-year age-classes), decennium,
sex and tobacco smoking or use of moist snuff.
In a post-hoc analysis we stratified for sex of the
participants.
Relative risks were estimated from Poisson regression
analysis. 95% confidence intervals were calculated by Wald
estimates.
We used statistics software SAS® 9.3 to calculate statis-
tics. P-values <0.05 were considered statistically significant.
A post-hoc power calculation (assuming a baseline preva-
lence of 0.16% for diagnosed CD among non-smokers)
showed that we had an 80% power at 5% significance level
to detect either a 29% increased risk or a 23% decreased
risk of CD among smokers.
Ethics
This study was approved by the Regional Ethical Review
Board in Umeå (2013/225-31).
Results
In the cohort of construction workers we identified 656
individuals (0.2%) with a biopsy-verified diagnosis of CD,
597 men and 59 women. They were on average 54.8 years
old at time of diagnosis and the time between diagnosis
and first health examination at “Bygghälsan” was 19.6 years
(range 0-35 years). Of these 488 had available data on
smoking status and 310 had data on moist snuff.
Smoking and CD
The cases with CD in the cohort had similar distribution
of smoking habits as the total cohort, (Table 1). The risk
of CD was independent of smoking status (and timesince health check-up) with all RRs being statistically in-
significant and ranging between 0.9 and 1.0 (Table 2).
Adjusted risk estimates were similar in moderate smokers
(RR = 0.92; 95% CI = 0.72-1.16) and heavy smokers (RR =
0.95; 0.74-1.24), and did not change when we examined
the risk more than ten years after health examination
(RR-moderate: 0.90; and RR-heavy: 0.95; both p > 0.05)
(Table 2). As some other studies have estimates for current
smokers we have also calculated risk estimates for the
combined group of moderate and heavy smokers (0 years
after examination RR = 0.93; 95% CI 0.76-1.14 and 10-
years after examination RR = 0.92; 95% CI. 0.74-1.15).
Moist snuff use and CD
Moist snuff use was not associated with CD (RR = 1.00;
0.78-1.28). When restricting our analysis to follow-up
after more than ten years after the health examination,
the adjusted RR was 1.05 (95% CI = 0.80-1.38).
Tobacco smoking and use of moist snuff and CD
We also compared the risk of CD in those who both
smoked and used moist snuff compared with no use of
tobacco products. The analysis was restricted to men
with data on both smoking habits and use of moist snuff
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tween use of tobacco and never using moist snuff or
smoking (RR = 0.91; 0.69-1.19).
Posthoc analyses stratified for sex
A posthoc analysis restricted to only women showed an
inverse risk with smoking (RR for current smokers 0.46
(0.22-0.96). An analysis restricted to only men showed
no association with smoking (current smokers RR 0.98
95% CI 0.79-1.21).
Discussion
This prospective cohort study found no association be-
tween smoking, moist snuff use and CD. In fact almost
all RRs were between 0.9 and 1.0. Relative risks for fu-
ture CD did not change when we required a 10-year-
latency from health examination (with smoking status)
and CD, and were similar in moderate (RR = 0.92) and
heavy smokers (RR = 0.95). Also the RRs for CD in moist
snuff users were around 1.
As can be seen from Figure 1, most earlier studies have
shown an inverse relationship between CD and current
smoking (none of them have looked at CD and moist
snuff use). The exceptions are our previous study [26] and
that of Patel et al. [25]. The current study found no associ-
ation between CD and smoking, and shares several traits
with our study from 2005 [26]. In both studies were data
on smoking collected prospectively and independently
of the CD diagnosis. The two studies are also the biggest
so far (see legend, Figure 1) resulting in high study power
and narrow confidence intervals. The 95% CI for CD in
current smokers ranged between 0.76 and 1.14 in our
present study.
As for ex-smoking and CD, all earlier studies have
shown higher ORs than for current smoking (OR = 0.52
[23], 0.71 [24], 0.99 [20]; and in an Argentinean study
the negative relationship with current smoking (OR =
0.39) even turned into a positive one for ex-smoking
(OR = 1.46) [19]). The OR for ex-smoking and CD was
almost identical to that of current smoking in the study
from the Mayo clinic by Patel et al (1.6 [25]), and simi-
larly in the current study where the ex-smoking RR was
absolutely neutral (0.98).
As the collection of data on smoking and moist snuff
was prospective and independent of that of CD, we are
likely to have eliminated recall bias and selection bias
with regards to controls. In contrast, several older stud-
ies have drawn controls from inpatients (ear-nose and
ortopedics [23]; trauma and orthopedics [22]). This may
well overestimate the smoking rate in controls since
smokers are at increased risk of both ear-nose disease
and fractures; and such controls subsequently underesti-
mate the OR for CD among smokers. There is also a risk
that some earlier studies have identified individuals witha more severe CD than in the average patient with CD
since studies were limited to one (sometimes tertiary)
centre [19,22,23,25], and this may bias the RRs in either
direction. If the diagnosis of CD is depending on socio-
economic factors an inverse relation with smoking may
occur as persons with low socioeconomic status usually
smoke more today and may have lower availability to
medical care in some countries. Earlier reports of CD
and smoking have however shown that adjustment for
socioeconomic status [22,23] rarely influences the risk
estimates, and we recently showed that socioeconomic
status and education level are only of minor importance
for CD rates in Sweden [37]. The lack of association be-
tween CD and socioeconomic status in Sweden contrasts
with British data, and given that some of the strongest
inverse relationships between CD and smoking have
been seen in British studies [20,22-24] we cannot rule
out that country-specific factors and unidentified con-
founding have influenced risk estimates in our and earl-
ier studies. This said socioeconomic status is unlikely to
influence the current study more than marginally since
our study includes workers with similar socioeconomic
status for most occupational groups. However, we can-
not fully rule out a healthy worker effect. If smoking is
primarily associated with severe symptoms (classical CD
[38]), and such symptoms prohibit individuals from
working we may have underestimated an association
(positive or negative) between CD and smoking.
In the current study, data on smoking were obtained
through standardized questionnaires and sometimes
with the assistance of nurses. Also earlier studies have
used either questionnaires [20,24,25] or personal inter-
views [19,23] (or a combination [26,39]) to collect data.
The proportion of current smokers (41%) in our study
was higher than in most earlier studies (proportion among
controls: 10% [25], 13% [24], 24% (overall smoking rate
[26]), 30% [23], 33% [19,20,22], and 42% [21]) but our rate
is nevertheless consistent with Swedish national data from
the 1970s-1990s. Of note, a high proportion of smokers
will per se not influence RRs, but rather increase study
power.
Some 95% of our study population consisted of males.
This contrasts with other studies where women have
dominated (females with CD: 56% [25], 66% [22,24], 67%
[23], 73% [20], 83% [19], 100% [26]). Still, our study in-
cluded more than 15,000 females. Females had higher
risk of CD than men. The estimates in our study were
otherwise adjusted for sex by a categorical variable. A
posthoc analysis restricted to only women showed an in-
verse risk with smoking (RR for current smokers 0.46,
while no inverse relationship was seen in men (current
smokers RR 0.98). Women in this cohort include a rather
large group of office workers. Analysing women adjusting
for being an office worker or not showed a slightly lower
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two groups of women showed similar results (RR = 0.36
and RR = 0.36) but with wider confidence limits. Thus,
our data indicate that CD may be inversely associated to
smoking in women but not in men. These findings con-
trast with our earlier study where we saw no relationship
between smoking and CD in a female population [40].
One explanation for the difference between the two stud-
ies is that the former [40] was limited to women becoming
pregnant (potentially different from the general CD popu-
lation), but also that the CD diagnosis in our 2005 paper
[40] was based on the inpatient diagnosis of CD, rather
than biopsy-verified CD (current paper). Interaction be-
tween smoking and sex has been seen for other immune-
mediated diseases such as rheumatoid arthritis [41]. Sex
may also influence disease phenotype [42]. If smoking in-
fluences age at symptom onset that could also have influ-
enced our findings since the median age at CD diagnosis
was almost 55 years in this study, and our pregnancy-
smoking paper was based on women aged 15-44 years
[40], with most women being between 20 and 34 years
old.
Finally, our cohort includes rather few women with
CD (n = 43) and mostly non-smokers (n = 27) and fewer
current smokers (n = 10) and ex-smokers (n = 6) so the
negative relationship between CD and smoking may also
be a chance finding. It should be stressed that the 95%
CIs overlapped between men and women.
We did not have data on symptoms. We cannot rule
out that if an inverse relationship with smoking is re-
stricted to patients with classical [38] symptoms we
might have missed it. For instance Snook et al [22] only
included patients with diarrhoea and malabsorption.
Considering that symptoms in adult CD seems to have
changed [43,44], the relevance of studies restricted to
patients with malabsorption can be questioned. When
we reviewed patient charts from a random subset of in-
dividuals CD [33], diarrhoea occurred in 36% of our ce-
liac patients, this is almost identical to that of patients
with CD diagnosed later than year 2000 in a US centre
(37%) [43]. Still we cannot rule out that the composition
of celiac cases in our study differs slightly from that of
studies where data collection on CD took place in the
1990s [19,20,23-25] or earlier [22], and that decade may
have influenced our risk estimates. In our study, RRs
generally increased (became “less inverse”) after adjust-
ment for decade (data not shown).
In 2001, Prasad reported that anti-endomysial status
may be important to smoking among patients with CD
[45]. In their paper, EMA-negative status was strongly
associated with smoking (OR = 7.0) [45]. The use of ce-
liac serology to identify individuals with CD has in-
creased greatly in the last 15-20 years, and it is possible
that the association between CD and smoking is lessinverse in serology-positive individuals. Results by West
et al [24] argue against this as their celiac study popula-
tion consisted of EMA-positive individuals. Although
the current study did not require a positive celiac ser-
ology for the diagnosis of CD, some 88% with available
data on serology were positive at time of small intestinal
biopsy [33].
To our knowledge, this is the first prospective study
on smoking, moist snuff use and CD. The RRs for CD
among moist snuff users were consistently around 1, in-
dicating that the nicotine levels of moist snuff are un-
likely to protect against future CD.
This paper has some strengths and limitations. We
identified individuals with CD using biopsy report data
from 28 Swedish pathology departments and should
hence have identified an average celiac population since
more than 96% of all Swedish gastroenterologists and
paediatricians biopsied their patients before CD diagno-
sis at the time of data collection [33].
When we validated 114 randomly selected patients
using patient charts, we found that 95% of patients with
villous atrophy had CD [33]. We also reviewed >1500 bi-
opsy reports with villous atrophy and inflammation [33],
and other diagnoses than CD were then very uncommon
(the most common non-CD diagnosis recorded in biopsy
reports with villous atrophy was IBD, seen in 0.3% of the
reports) [33]. In other settings, other disorders such as
autoimmune enteropathy, Whipple disease, common vari-
able immunodeficiency, giardiasis and cow-milk protein
intolerance should be considered in patients with villous
atrophy [46].
A limitation of our study is that we did not screen for
CD in our population. Considering that this study in-
volved more than 300,000 individuals this was not feas-
ible. Lack of serological screening might have been a
problem if smoking was linked to CD with minor symp-
toms (and remaining undiagnosed) but considering that
some of the lowest risk estimates for CD (OR = 0.15)
was seen in the study by Snook et al [22] where all pa-
tients suffered from malabsorption and diarrhoea this is
unlikely to be the case. In a subset of patients where we
had access to patient chart data [33], some 79% of CD
patients had gastrointestinal symptoms.
An additional study limitation is that we were unable
to identify individuals who might have quit smoking
after the first data collection. Finally, despite the large
number of study participants we cannot rule out a minor
inverse or positive association between CD and smoking
due to limited study power.
Smoking influences the immune system and more spe-
cifically may decrease the intestinal permeability [47].
This could potentially protect against gliadin exposure
and risk of CD, and has been argued as the cause for earl-
ier findings of an inverse relationship between smoking
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flammation our data argue that substances that only occur
in tobacco smoke are unlikely to explain an inverse rela-
tionship with CD since risk estimates in our study were al-
most identical in smokers and moist snuff users. However,
the most likely explanation for RRs around 1 in both
smokers and moist snuff users are that these factors do
not play a major role in the aetiology of CD in a Swedish
setting.
Conclusions
In conclusion, we found no association between smoking,
moist snuff use and CD.
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